restenosis

(redirected from Coronary restenosis)
Also found in: Medical.

Translations

re·ste·no·sis

n. reestenosis, recurrencia de estenosis después de cirugía correctiva.

restenosis

n reestenosis f

References in periodicals archive ?

Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimuseluting stent versus a standard stent in patients at high risk for coronary restenosis.

Impact of stent length and diameter on short term clinical outcomes of drug eluting stents in patients with stable coronary artery disease

Eluting stents principles / or active / or who have demonstrated efficacy in the prevention of coronary restenosis preassembled on the catheter balloon slotted tube type, ring or multidesign mounted on balloon monorail suitable for the complete expansion of the stent, with a length of 8-9, 12 -15, 16-22, 24-32 and 38 mm and diameters between 2.

Supply Of Coronary Stents And Balloon Angioplasty Coronarica

Coronary stents provide a path to the blood flow in the blocked coronary arteries in patients suffering from the condition of coronary restenosis.

Healthcare Industry : The US Coronary Stent Industry Research Report

Thus far, however, it has proven difficult to stratify patients with regard to risk for coronary restenosis based only upon clinical, angiographic or procedural risk factors.

An important role for VCAM-1, but not for ICAM-1 in restenosis following coronary stent implantation/ Koroner stent implantasyonu sonrasi restenozda ICAM-1'e gore VCAM-1 'in onemli rolu

A paclitaxel-eluting stent for the prevention of coronary restenosis.

New generation sirolimus eluting PTCA angioplasty balloon catheter for restenosis therapy

Two major processes are involved in adverse events following PCI: (a) coronary restenosis, and (b) progression of disease on the same vessel or in another vessel (2).

Preprocedural C-reactive protein for risk prediction before percutaneous coronary intervention (PCI): a European perspective

The prospective, randomized, double-blind trial is designed to assess the safety and efficacy of a slow-release dose formulation paclitaxel-eluting TAXUS stent system for the treatment of coronary restenosis.

BSC GETS IDE APPROVAL TO BEGIN TAXUS IV CLINICAL TRIAL

Potential role of human cytomegalovirus and p53 interaction in coronary restenosis.

Potential infectious etiologies of atherosclerosis: a multifactorial perspective. (Synopses)

Cardiologists often treat secondary blockages, called coronary restenosis, by removing the clogging clump of cells.

Heart vessel clogs linked to p53

Updates will be presented on the Treatment of Acute Coronary Syndromes, Coronary Restenosis, Syncope and Congestive Heart Failure as well as on the Use of MRI in Cardiac Disease and on Hyperlipidemia.

Cardiovascular Summit II: ``A Climate for Learning''

The recently completed START trial demonstrated the efficacy of beta radiation for the treatment of coronary restenosis.